Kalimuthu Karuppanan
Dr. Kalimuthu Karuppanan obtained his Ph.D. in Biotechnology from Madurai Kamaraj University, India (2013). He was a postdoctoral scientist and Lecturer in Department of Chemical Engineering, University of California, Davis, USA (2014-2018). He relocated for his second postdoctoral scientist position in Radcliffe Department of Medicine, University of Oxford, UK (2019-2021). Also, he was a Co-Investigator in Center for the Utilization of Biological Engineering in Space (CUBES) project, NASA-Space technology Research Institutes, USA, and Co-Investigator in Emergency Response to the Novel Coronavirus Pandemic (COVID-19) project funded by KFAS-Kuwait University, Kuwait. Currently he is working as a research faculty at SRM Institute of Science and Technology, KTR, India. He has contributed to various therapeutic protein engineering and developments (including Zmapp cocktail antibodies for Ebola and Fc fusion proteins for SARS-CoV-2 infection). He has one approved US patent, various prestigious drug discovery awards and peer-reviewed journal publications for his research accomplishment in Biotherapeutics.